PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Stocks in this Quantisnow insightHealth Care
Historical context for PEPG
Across the 7 sessions after earlier PEPG headlines, the stock closed higher 3 times and lower 4 times, with a median move of 2.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | PEPG | SPY |
|---|---|---|---|
| Mar 31, 2026 | PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data | -58.2% | +2.9% |
| Mar 5, 2026 | PepGen Announces Regulatory Updates on FREEDOM2 | -18.6% | -0.6% |
| Mar 3, 2026 | PepGen to Participate in the Leerink Global Healthcare Conference | -1.7% | -0.9% |
| Dec 9, 2025 | PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer | +2.0% | -0.1% |
| Dec 8, 2025 | PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer | +2.8% | -0.3% |
| Nov 12, 2025 | PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Moleculeand 1 other headline that session | +10.3% | +0.1% |
Quantisnow market dataNASDAQ
PEPG
PepGen Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2022
Get push alerts for PEPG
Full PEPG profile on Quantisnow Follow PEPG and get a push notification the moment its next story breaks.